A pilot study of combination monoclonal antibody treatment in early ac
A pilot study of combination monoclonal antibody treatment in early active relapsing-remitting multiple sclerosis using Campath-1H and its non-binding form, SM3.
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Alemtuzumab
CAMPATH-1 antigen inhibitor
What it measured
Main measures
Incidence of anti-alemtuzumab antibodies
Who could take part
Relapsing MS
Show the full criteria
Inclusion criteria
Inclusion: • Male or non-pregnant, non-lactating female patients, 18 to 50 years of age (inclusive) Exclusion: • Detectable anti-Campath-1H antibodies
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The primary objective of this study is to assess the ability of SM3 to tolerise patients with multiple sclerosis to the therapeutic antibody alemtuzumab. The incidence of anti-alemtuzumab antibodies following two doses of alemtuzumab alone will be compared with that achieved by two doses of alemtuzumab preceded by SM3
Loading reviews and guidelines…
Related trials
- The HIt HArd and hiT Early in Multiple Sclerosis Trial
Phase 2 · Recruiting
Still running
- Effects of CLADribine tablets on the Immune Synapse, in Relapsing Mult
Phase 4 · Not yet recruiting
Still running
- No Evidence Of Disease Activity After Autologous Haematopoietic Stem C
Phase 2 · Stopped early
Stopped
- Cladribine Tablets Level of Response Predictors in Clinical Practice (
Running, not recruiting
Still running
- ADAs to Alemtuzumab
Completed
No results found
- A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY
Running, not recruiting
Still running
History
Started
Jan 2008